Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.62 |
| ▸ | WNT3A | P56704 | 2/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416831 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL8269548 | 0.92 | HSD11B1 (0.64) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL28188567 | 0.90 | PDE4B (0.67) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL4884872 | 0.90 | PDE4B (0.62) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL3588375 | 0.85 | CTNNB1 (0.60) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL8098826 | 0.85 | PARP1 (0.65) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL30416977 | 0.85 | CTNNB1 (0.60) | ALDH1A1CYP1A2HPGDCYP2C19HSD17B10 | |
| SCHEMBL1421198 | 0.85 | CES2 (0.62) | CES2CES1HSD11B1PARP1HTT | |
| SCHEMBL4637827 | 0.85 | CES2 (0.62) | ALDH1A1HPGDCTNNB1WNT3ACES2 | |
| SCHEMBL19984838 | 0.85 | CES2 (0.62) | ALDH1A1CTNNB1WNT3ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106242957-A | A kind of preparation method of 2 bromine 3 ' methoxyacetophenones | 湖北欣瑞特医药科技有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-101600689-A | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (VG) | 2009-12-09 | — | — | CN | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007047394-A2 | THIOTRIAZOLYL DERIVATIVES | EPIX DELAWARE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047394-A2 | THIOTRIAZOLYL DERIVATIVES | EPIX DELAWARE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5338739-A | Memory dysfunction relieving compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0115133-B1 | SPIRO-3-HETERO-AZOLONES FOR TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4556670-A | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0115133-A1 | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| US-4201869-A | Intermediates for steroid total synthesis process utilizing asymmetric induction | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4102925-A | 1-HYDROCARBYLAMINO-3-KETO-6-(3-ALKOXY-PHENYL)-HEXAN-6-OL, INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4092483-A | Intermediates for steroid total synthesis process utilizing asymmetric induction | HOFFMANN-LA ROCHE INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4011211-A | RING CLOSURE, ACIDS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-4003949-A | 3-KETO-6-(3-ALKOXYPHENYL)-1-HEXENE-6-OL | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3932519-A | 7,7A-Dihydro-4-[2-(3-alkoxyphenyl)-2-hydroxyethyl]-7a-alkyl-1, 5(6H)-indandiones,3,4,8,8a-tetrahydro-5-[2-(3-alkoxyphenyl)-2-hydroxyethyl]-8a-alkyl-1,6(7H)-naphthalenediones and processes for the preparation thereof utilizing asymmetric induction | HOFFMANN-LA ROCHE INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | ALDH1A1 4054/4885CYP1A2 2612/4885HPGD 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.